Physician profile
John M White
NPI 1558389833
$1,713.94
in general payments reported to CMS, 2019-2025
19 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $119 · 2023: $621 · 2024: $317 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $412.42 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $376.85 | 2021-2025 | Entyvio, Gattex |
| Abbvie INC. | $315.49 | 2021-2025 | |
| Madrigal Pharmaceuticals | $163.18 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.55 | 2021-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $35.51 | 2023-2024 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $33.75 | 2022-2023 | Injectafer |
| Olympus America INC. | $33.59 | 2025 | Evis Exera III Video System Center |
| Ironwood Pharmaceuticals, INC | $24.73 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.97 | 2025 | Iqirvo |
| Novo Nordisk INC | $21.97 | 2025 | Wegovy |
| Janssen Biotech, INC. | $21.15 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $19.77 | 2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $16.18 | 2025 | Terlivaz |
| Braintree Laboratories, INC. | $14.29 | 2024 | Sutab, Suflave |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $13.75 | 2023 | Gimoti |
| Ardelyx, INC. | $13.45 | 2023 | Ibsrela |
| Lilly USA, LLC | $13.30 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $13.04 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.